United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Raises Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• United Super Pty Ltd increased its holdings in Gilead Sciences, purchasing 7,100 shares and raising its position by 263.0% in Q1, bringing total ownership to 9,800 shares valued at approximately $1,098,000.
• Several large investors have also increased or established new stakes in Gilead, reflecting strong institutional interest with 83.67% of the stock owned by institutional investors.
• CEO Daniel Patrick O'Day and CFO Andrew D. Dickinson recently sold shares, indicating insider trading activity with total sales amounting to over $1.4 million in the last quarter.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 263.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 9,800 shares of the biopharmaceutical company's stock after purchasing an additional 7,100 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund's holdings in Gilead Sciences were worth $1,098,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. FMR LLC raised its holdings in shares of Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after buying an additional 2,532,070 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the last quarter. Los Angeles Capital Management LLC raised its holdings in shares of Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock worth $282,706,000 after buying an additional 2,040,261 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of Gilead Sciences by 30.1% in the fourth quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock worth $801,655,000 after buying an additional 2,005,863 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded up $0.89 during trading on Friday, hitting $113.18. The company had a trading volume of 5,016,320 shares, compared to its average volume of 5,536,027. The stock has a fifty day simple moving average of $110.51 and a two-hundred day simple moving average of $106.91. Gilead Sciences, Inc. has a fifty-two week low of $72.43 and a fifty-two week high of $119.96. The firm has a market capitalization of $140.79 billion, a price-to-earnings ratio of 23.83, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.

Analysts Set New Price Targets

A number of research analysts have issued reports on GILD shares. Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $112.36.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $333,090.00. Following the sale, the insider owned 117,168 shares in the company, valued at $13,009,163.04. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $8,984,175 in the last ninety days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.